SPOTLIGHT: Bioheart stumbles out of the IPO gate

Going public wasn't easy for Bioheart. After delaying its IPO twice and slashing its prospective share price from a range of $14 to $16 to $6 to $8, the Sunrise, FL-based biotech saw its share price quickly slip from its $5.25 a share offering on its first day of trading on Tuesday. The biotech raised about $5.8 million in a tough market. Much of that money will go to funding clinical trials of its cell therapy for heart damage. Release | Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.